Habermann TM - Search Results

1

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.

Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Witzig TE, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ. Wenzl K, et al. Among authors: habermann tm. Blood Cancer J. 2024 Jun 20;14(1):100. doi: 10.1038/s41408-024-01080-0. Blood Cancer J. 2024. PMID: 38902256 Free PMC article.

2

Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section method.

Witzig TE, Banks PM, Stenson MJ, Griepp PR, Katzmann JA, Habermann TM, Colgan JP, Gonchoroff NJ. Witzig TE, et al. Among authors: habermann tm. Am J Clin Pathol. 1990 Sep;94(3):280-6. doi: 10.1093/ajcp/94.3.280. Am J Clin Pathol. 1990. PMID: 2204263

3

Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.

Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM, Kyle RA. Greipp PR, et al. Among authors: habermann tm. Mayo Clin Proc. 1987 Nov;62(11):969-77. doi: 10.1016/s0025-6196(12)65066-6. Mayo Clin Proc. 1987. PMID: 3118117

4

S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma.

Witzig TE, Habermann TM, Kurtin PJ, Schroeder G, Stenson MJ, Greipp PR. Witzig TE, et al. Among authors: habermann tm. Cancer. 1995 Sep 15;76(6):1059-64. doi: 10.1002/1097-0142(19950915)76:6<1059::aid-cncr2820760621>3.0.co;2-e. Cancer. 1995. PMID: 8625208

5

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Ansell SM, et al. Among authors: habermann tm. J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296. J Clin Oncol. 1997. PMID: 9196143

6

Primary laryngeal lymphoma.

Ansell SM, Habermann TM, Hoyer JD, Strickler JG, Chen MG, McDonald TJ. Ansell SM, et al. Among authors: habermann tm. Laryngoscope. 1997 Nov;107(11 Pt 1):1502-6. doi: 10.1097/00005537-199711000-00014. Laryngoscope. 1997. PMID: 9369397

7

A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.

Witzig TE, Camoriano JK, Schroeder G, Kurtin PJ, Habermann TM. Witzig TE, et al. Among authors: habermann tm. Leuk Lymphoma. 1998 Jan;28(3-4):307-14. doi: 10.3109/10428199809092686. Leuk Lymphoma. 1998. PMID: 9517502 Clinical Trial.

8

Primary thyroid lymphoma.

Ansell SM, Grant CS, Habermann TM. Ansell SM, et al. Among authors: habermann tm. Semin Oncol. 1999 Jun;26(3):316-23. Semin Oncol. 1999. PMID: 10375088 Review.

9

Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index.

Ansell SM, Kurtin PJ, Stenson M, Habermann TM, Greipp PR, Therneau TM, Witzig TE. Ansell SM, et al. Among authors: habermann tm. Leuk Lymphoma. 1999 Aug;34(5-6):529-37. doi: 10.3109/10428199909058480. Leuk Lymphoma. 1999. PMID: 10492076

10

Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.

O'Neill BP, Habermann TM, Witzig TE, Rodriguez M. O'Neill BP, et al. Among authors: habermann tm. Med Oncol. 1999 Sep;16(3):211-5. doi: 10.1007/BF02906134. Med Oncol. 1999. PMID: 10523802

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

435 results

Search Page

Filters